Esther J. Kret

Esther J. Kret

Auto-generated profile, based on publicly available information

Esther J. Kret

Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2025 in Blood Advances
Verified
Journal Article
Open access
JBJanneke de Boer
Janneke de Boer
KKKylie Keijzer
Kylie Keijzer
SDSuzanne van Dorp
Suzanne van Dorp
PMPim Mutsaers
Pim Mutsaers
ANAnne G. H. Niezink
Anne G. H. Niezink
TMTom van Meerten
Tom van Meerten
Early identification of patients at risk of immune effector cell–associated hematotoxicity (ICAHT) is essential to minimize nonrelapse mortality. The CAR-HEMATOTOX (HT) score is an implemented risk-stratification tool for ICAHT, infections, and survival in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) receiving chimeric antigen receptor T-cell therapy (CART). Although validated in its defining study, the HT score was developed in a small cohort, necessitating independent external validation. This study externally validates the HT score in a real-world population-based cohort of adults with R/R LBCL receiving CART. The HT score, based on absolute neutrophil count (ANC), hemoglobin, platelets, C-reactive protein, and ferritin, was calculated before lymphodepleting chemotherapy. Of 245 consecutive patients, 171 (70%) had an HT score of ≥2 (HThigh). The initial end point, clinically significant neutropenia (ANC of <500/μL for ≥14 days), occurred in 21% of patients. The binary HT score was associated with clinically significant neutropenia (odds ratio [OR], 2.94; 95% confidence interval [CI], 1.27-6.80; P = .012) with a good predictive performance (area under the curve = 0.73). Similar results were achieved for early and late ICAHT grade ≥3 (OR, 2.92; 95% CI, 1.19-7.14; P = .019; and OR, 2.42; 95% CI, 1.31-4.47; P = .005). A trend toward an association with severe infections was observed (OR, 2.02; 95% CI, 0.91-4.48; P = .085). HThigh patients had a lower progression-free and overall survival (hazard ratio [HR], 1.84; 95% CI, 1.15-2.93; P = .011; and HR, 2.83; 95% CI, 1.64-4.87; P < .001, respectively). The HT score identified CART-treated patients with R/R LBCL at risk of clinically significant neutropenia, poor survival outcomes, and potentially severe infections.

29 April 2025 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
RGRuben de Groen
Ruben de Groen
FGFleur A. de Groot
Fleur A. de Groot
SBStefan Böhringer
Stefan Böhringer
EKEsther J. Kret
Esther J. Kret
LHLorraine M. de Haan
Lorraine M. de Haan
Joost S VermaatJoost S Vermaat
Joost S Vermaat
With tumor genomic and gene-expression profiling (GEP), this study investigated the immune-molecular signatures of a unique cohort of diffuse large B-cell lymphoma of the bone (bone-DLBCL), including primary bone (PB-DLBCL, n = 52) and polyostotic-DLBCL (n = 20), in comparison to nodal DLBCLs with germinal center B-cell (GCB) phenotype (nodal-DLBCL-GCB, n = 34). PB-DLBCL and polyostotic-DLBCL shared similar genomic profiles and transcriptomic signatures, justifying their collective analysis as bone-DLBCL. Differential incidences of EZH2, HIST1H1E, and MYC aberrations (p < 0.05) confirmed the distinct oncogenic evolution between bone-DLBCL and nodal-DLBCL-GCB. Differentially expressed genes were identified between bone-DLBCL and nodal-DLBCL-GCB (p < 0.001), substantiated by distinct gene-set enrichment analysis (GSEA). In contrast to a more ‘depleted’ phenotype for nodal-DLBCL-GCB, bone-DLBCL primarily exhibited an ‘intermediate/rich’ tumor microenvironment (TME) signature (p = 0.001), as determined by a previously published gene set. Unsupervised clustering defined two distinct groups that aligned with previously reported immune-enriched TME clusters: an ‘immune-rich’ cluster largely consisting of bone-DLBCLs (75%, p = 0.002) with superior survival (p = 0.030), and a poor-prognostic ‘immune-low’ cluster, including mostly nodal-DLBCL-GCB (61%). Single-sample (ss)GSEA showed higher scores for regulatory T cells, immunosuppressive/prolymphoma cytokines, and vascular endothelial cells in immune-rich samples (p < 0.001). Additionally, CIBERSORTx revealed a higher abundance of regulatory T cells and activated mast cells in the immune-rich cluster (p < 0.001). These findings were confirmed at protein level, where CD3 and FOXP3 immunochemistry showed significant overlap with the gene-expression data (p < 0.001). Conclusively, PB-DLBCL and polyostotic-DLBCL share immune-molecular TME characteristics, supporting their classification as a unified bone-DLBCL entity. The distinct immune-rich TME profile of bone-DLBCL associated with superior survival potentially shapes emerging immunomodulatory strategies

1 April 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
DMD P ter Meulen
D P ter Meulen
MMM A M Mulders
M A M Mulders
AKAnouk Anne Kruiswijk
Anouk Anne Kruiswijk
EKE J Kret
E J Kret
MSM E Slichter
M E Slichter
RPR W Poolman
R W Poolman
Introduction Current literature is inconclusive about the optimal treatment of elderly patients with displaced intra-articular distal radius fractures. Cast treatment is less invasive and less expensive than surgical treatment. Nevertheless, surgery is often the preferred treatment for this common type of distal radius fracture. Patients with a non-acceptable position after closed reduction are more likely to benefit from surgery than patients with an acceptable position after closed reduction. Therefore, this study aims to assess non-inferiority of functional outcomes after casting versus surgery in elderly patients with a non-acceptable position following a distal radius fracture. Methods and analysis This study is a multicentre randomised controlled trial (RCT) with a non-inferiority design and an economic evaluation alongside. The population consists of patients aged 65 years and older with a displaced intra-articular distal radius fracture with non-acceptable radiological characteristics following either inadequate reduction or redisplacement after adequate reduction. Patients will be randomised between surgical treatment (open reduction and internal fixation) and non-operative treatment (closed reduction followed by cast treatment). We will use two age strata (65–75 and >75 years of age) and a web-based mixed block randomisation. A total of 154 patients will be enrolled and evaluated with the patient-rated wrist evaluation as the primary outcome at 1-year follow-up. Secondary outcomes include the Disabilities of the Arm, Shoulder and Hand questionnaire, quality of life (measured by the EQ-5D), wrist range of motion, grip strength and adverse events. In addition, we will perform a cost-effectiveness and cost-utility analysis from a societal and healthcare perspective. Incremental cost-effectiveness ratios, cost-effectiveness planes and cost-effectiveness acceptability curves will be presented. Ethics and dissemination The Research and Ethics Committee approved this RCT (NL56858.100.16). The results of this study will be reported in a peer-reviewed journal. We will present the results of this study at (inter)national conferences and disseminate the results through guideline committees. Trial registration number Clinicaltrials.gov (NCT03009890). Dutch Trial Registry (NTR6365).

1 July 2025 in JBJS Open Access
Verified
Journal Article
Open access
DMDirk P. ter Meulen
Dirk P. ter Meulen
CSCaroline A. Selles
Caroline A. Selles
EKEsther J. Kret
Esther J. Kret
AKAnouk Anne Kruiswijk
Anouk Anne Kruiswijk
MSMalou E. Slichter
Malou E. Slichter
DGDART Study Group
DART Study Group
Background: Evidence supporting surgery in elderly patients with distal radius fractures is limited, but displaced fractures may benefit from surgery. This study aimed to determine whether casting is noninferior to surgery for patients aged 65 years or older with substantially displaced intra-articular (AO type C) distal radius fractures. Methods: This multicenter randomized controlled noninferiority trial included 138 patients (mean age 76 years, SD 6.0) in 19 Dutch hospitals. 138 patients were randomized with a mean age of 76 years (SD 6.0). After 12 months, 126 patients (91%) completed the trial. All patients had a nonacceptable fracture position according to the guideline after reduction. Patients were randomized between casting and open reduction internal fixation (ORIF). The primary outcome was the Patient Rated Wrist Evaluation (PRWE) at the 1-year follow-up. Secondary outcomes included the Disability of the Arm, Shoulder, and Hand questionnaire; quality of life (measured by the EQ-5D-3L); range of motion; grip strength; and complications. Primary analyses were linear mixed models with an intention-to-treat approach. Results: The mean PRWE score at 1-year follow-up for the casting group was 20.4 (95% CI, 15.3-25.6) and in the surgical group was 14.5 (95% CI, 9.9-19.0). The primary intention-to-treat crude analysis was inconclusive regarding noninferiority, with a between-group difference of 6.0 points (95% CI, −2.1 to 14.1) in favor of surgery. However, noninferiority was demonstrated after correction for baseline covariates and in both as-treated analyses. The surgical group had better grip strength but significantly more reoperations (i.e., hardware removal). Subgroup analysis showed greater benefits of surgery in physiologically younger patients, while more frail patients had no advantage. Conclusions: The primary analysis did not demonstrate noninferiority of casting compared with surgery at 1-year follow-up in patients aged 65 years or older with substantially displaced intra-articular distal radius fractures. The benefit of surgery was consistent across multiple outcomes, most notably in the short term and for physiologically younger patients. Level of Evidence: RCT. Level I evidence. See Instructions for Authors for a complete description of levels of evidence.